NTx 488 regimen - Trillium Therapeutics Inc

Drug Profile

NTx 488 regimen - Trillium Therapeutics Inc

Alternative Names: NTx-488

Latest Information Update: 16 Jun 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stem Cell Therapeutics Corp.
  • Developer Trillium Therapeutics Inc
  • Class Erythropoietins; Peptide hormones; Pituitary gonadotropins
  • Mechanism of Action Cell differentiation stimulants; Erythropoietin receptor agonists; Neuron stimulants; Ovarian follicle stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 02 Jun 2014 Stem Cell Therapeutics is now called Trillium Therapeutics
  • 25 Jul 2013 Discontinued - Preclinical for Multiple sclerosis in Canada (Parenteral)
  • 25 Jul 2013 Stem Cell Therapeutics' NTx 488 regimen research programme is available for licensing as of 25 Jul 2013. http://www.stemcellthera.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top